Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CK Life Sciences International Holdings's revenue per share for the
six
months ended in Jun. 2026 was $0.04.
CK Life Sciences International Holdings's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.07.
Warning Sign:
CK Life Sciences International Holdings Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of CK Life Sciences International Holdings was 0.70% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 0.80% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 1.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
CKLSF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.8 Med: 2.7 Max: 357.9
Current: 0.8
During the past 13 years, CK Life Sciences International Holdings's highest 3-Year average Revenue Per Share Growth Rate was 357.90% per year. The lowest was -1.80% per year. And the median was 2.70% per year.
CKLSF's 3-Year Revenue Growth Rate is ranked worse than 53.13% of 768
companies
in the Biotechnology industry
Industry Median: 2.95
vs CKLSF: 0.80
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
CK Life Sciences International Holdings Revenue per Share Related Terms
CK Life Sciences International Holdings Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Revenue per Share Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, RVMD: Revenue per Share Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings PS Ratio vs Biotechnology Industry
CK Life Sciences International Holdings Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (CKLSF) has a Revenue per Share of $0.07 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #408 out of 768 companies in the Biotechnology industry, placing it in the top 53.1%.
Is CK Life Sciences International Holdings' Revenue per Share too high?
CK Life Sciences International Holdings' current Revenue per Share is $0.07. The Biotechnology industry median Revenue per Share is 2.95. CK Life Sciences International Holdings' value of $0.07 is 97.6% below this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #408 out of 768 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #408 out of 768 companies for Revenue per Share. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median Revenue per Share is 2.95. CK Life Sciences International Holdings' value of $0.07 is 97.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 2.95, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Revenue per Share of $0.07 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median Revenue per Share is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Revenue per Share is $0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
Based on GuruFocus' analysis, CK Life Sciences International Holdings (CKLSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30.7% below its estimated fair value. The current Revenue per Share is $0.07 and 97.6% below the Biotechnology industry median of 2.95. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Revenue per Share is $0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.07 is trading 30.7% below its estimated GF Value™ of $0.10.
GuruFocus considers CK Life Sciences International Holdings to be Possible Value Trap.
Key valuation signals for CKLSF:
Revenue per Share: $0.07
GF Value™: $0.10 vs. price of $0.07 (30.7% below fair value)
Industry Position: 97.6% below the Biotechnology median (#408 of 768)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for CKLSF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
